Paul E. Freiman - 11 May 2023 Form 4 Insider Report for NovaBay Pharmaceuticals, Inc. (NBY)

Role: Director
Signature: /s/ Justin Hall as attorney in fact for Paul E. Freiman
Issuer symbol: NBY
Transactions as of: 11 May 2023
Net transactions value: $0
Form type: 4
Filing time: 15 May 2023, 18:54:26 UTC
Previous filing: 24 May 2022
Next filing: 13 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NBY	Common Stock	Options Exercise		+858	+100%		1,716	11 May 2023	Direct	F1, F2
holding	NBY	Common Stock						67	11 May 2023	By trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NBY	Restricted Stock Units	Options Exercise	$0	-858	-100%	$0.000000^*	0	11 May 2023	Common Stock	858		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On November 15, 2022, NovaBay Pharmaceuticals, Inc. effected a 1-for-35 reverse stock split of its common stock, which is reflected in the number of shares.
F2	Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vested on the one year anniversary of the date of grant.